Patients with PD-L1-high tumors (≥50% tumor cell staining) in this real-world cohort did not have improved TTP compared to PD-L1-negative and -low patients (HR = 0.86, p = 0.60, log-rank) (Fig. 1b). This evidence concerns the gene CD274 and neoplasm.